Johnson & Johnson logo
Johnson & Johnson (JNJ)
Compare

Johnson & Johnson (JNJ) EV/Sales Ratio: 6.00x

popular:market cap|pe ratio|revenue|price history|total return

Is Johnson & Johnson’s EV/Sales ratio high or low?

Johnson & Johnson's EV/Sales ratio of 6.00x is 19% above its 5-year average of 5.03x, near the high end of its 5-year range (4.11x–6.74x).

The EV/Sales ratio for Johnson & Johnson (JNJ) is 6.00x as of Wednesday, June 10, 2026. It is above its 12-month average by 7.34% (5.59x).

EV/EBITDA|P/S Ratio|Revenue|All Metrics

JNJ EV/Sales Ratio Chart

JNJ EV/Sales Ratio
6.00x+36.36% 1Y
Zoom

JNJ Average EV/Sales Ratio Chart

JNJ Current vs Average EV/Sales Ratio Chart

JNJ EV/Sales Ratio Metrics

EV/SALES RATIO

6.00x

EV/SALES RATIO AVG TTM

5.59x

EV/SALES RATIO AVG 3Y

4.96x

EV/SALES RATIO AVG 5Y

5.03x

EV/SALES RATIO AVG 10Y

4.98x

EV/SALES RATIO AVG 15Y

4.51x

EV/SALES RATIO AVG 20Y

4.13x

CURRENT VS TTM AVG

+7.34%

CURRENT VS 3Y AVG

+21.00%

CURRENT VS 5Y AVG

+19.36%

CURRENT VS 10Y AVG

+20.51%

CURRENT VS 15Y AVG

+33.01%

CURRENT VS 20Y AVG

+45.30%

JNJ Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Johnson & Johnson (JNJ)$574.15B6.00x5.59x4.96x5.03x
Pfizer Inc. (PFE)$146.36B3.31x3.30x3.43x3.63x
Merck & Co., Inc. (MRK)$293.02B5.13x4.33x4.75x4.77x
AbbVie Inc. (ABBV)$399.54B7.39x7.45x6.80x6.32x
Eli Lilly and Company (LLY)$1.07T14.66x14.55x17.60x14.77x
Bristol-Myers Squibb Company (BMY)$114.14B3.08x2.99x3.12x3.48x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Johnson & Johnson EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Johnson & Johnson EV/Sales Ratio FAQ

What is the EV/Sales ratio for Johnson & Johnson (JNJ)?
The EV/Sales ratio for JNJ stock is 6.00x.
Is Johnson & Johnson's EV/Sales ratio high or low?
Johnson & Johnson's EV/Sales ratio of 6.00x is 19% above its 5-year average of 5.03x, near the high end of its 5-year range (4.11x–6.74x).
What is the TTM average EV/Sales ratio for Johnson & Johnson (JNJ)?
The TTM average EV/Sales ratio for JNJ stock is 5.59x.
What is the 3Y average EV/Sales ratio for Johnson & Johnson (JNJ)?
The 3Y average EV/Sales ratio for JNJ stock is 4.96x.
What is the 5Y average EV/Sales ratio for Johnson & Johnson (JNJ)?
The 5Y average EV/Sales ratio for JNJ stock is 5.03x.
What is the 10Y average EV/Sales ratio for Johnson & Johnson (JNJ)?
The 10Y average EV/Sales ratio for JNJ stock is 4.98x.
What is the 15Y average EV/Sales ratio for Johnson & Johnson (JNJ)?
The 15Y average EV/Sales ratio for JNJ stock is 4.51x.
What is the 20Y average EV/Sales ratio for Johnson & Johnson (JNJ)?
The 20Y average EV/Sales ratio for JNJ stock is 4.13x.

Johnson & Johnson EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-106.00x
2026-06-095.97x
2026-06-085.85x
2026-06-055.86x
2026-06-045.75x
2026-06-035.62x
2026-06-025.61x
2026-06-015.63x
2026-05-295.67x
2026-05-285.81x
2026-05-275.83x
2026-05-265.80x
2026-05-225.90x
2026-05-215.84x
2026-05-205.78x
2026-05-195.79x
2026-05-185.77x
2026-05-155.71x
2026-05-145.81x
2026-05-135.80x
2026-05-125.65x
2026-05-115.57x
2026-05-085.57x
2026-05-075.60x
2026-05-065.66x
2026-05-055.68x
2026-05-045.65x
2026-05-015.72x
2026-04-305.79x
2026-04-295.73x
2026-04-285.74x
2026-04-275.67x
2026-04-245.73x
2026-04-235.81x
2026-04-225.69x
2026-04-216.16x
2026-04-206.27x
2026-04-176.36x
2026-04-166.37x
2026-04-156.48x
2026-04-146.52x
2026-04-136.46x
2026-04-106.47x
2026-04-096.55x
2026-04-086.55x
2026-04-076.47x
2026-04-066.54x
2026-04-026.59x
2026-04-016.62x
2026-03-316.63x
2026-03-306.58x
2026-03-276.53x
2026-03-266.49x
2026-03-256.51x
2026-03-246.39x
2026-03-236.40x
2026-03-206.39x
2026-03-196.45x
2026-03-186.44x
2026-03-176.47x
2026-03-166.60x
2026-03-136.55x
2026-03-126.57x
2026-03-116.59x
2026-03-106.61x
2026-03-096.58x
2026-03-066.52x
2026-03-056.50x
2026-03-046.65x
2026-03-036.69x
2026-03-026.74x
2026-02-276.73x
2026-02-266.60x
2026-02-256.65x
2026-02-246.68x
2026-02-236.67x
2026-02-206.58x
2026-02-196.69x
2026-02-186.64x
2026-02-176.60x
2026-02-136.60x
2026-02-126.63x
2026-02-116.54x
2026-02-106.58x
2026-02-096.59x
2026-02-066.62x
2026-02-056.57x
2026-02-046.48x
2026-02-036.44x
2026-02-026.38x
2026-01-306.29x
2026-01-296.29x
2026-01-286.30x
2026-01-276.21x
2026-01-266.14x
2026-01-236.10x
2026-01-226.06x
2026-01-216.04x
2026-01-206.05x
2026-01-166.06x
2026-01-156.09x
2026-01-146.06x
2026-01-135.93x
2026-01-125.83x
2026-01-095.69x
2026-01-085.72x
2026-01-075.77x
2026-01-065.70x
2026-01-055.68x
2026-01-025.76x
2025-12-315.75x
2025-12-305.75x
2025-12-295.77x
2025-12-265.77x
2025-12-245.78x
2025-12-235.72x
2025-12-225.76x
2025-12-195.74x
2025-12-185.79x
2025-12-175.84x
2025-12-165.82x
2025-12-155.94x
2025-12-125.88x
2025-12-115.83x
2025-12-105.74x
2025-12-095.57x
2025-12-085.61x
2025-12-055.62x
2025-12-045.64x
2025-12-035.71x
2025-12-025.71x
2025-12-015.71x
2025-11-285.75x
2025-11-265.77x
2025-11-255.75x
2025-11-245.73x
2025-11-215.67x
2025-11-205.65x
2025-11-195.64x
2025-11-185.57x
2025-11-175.56x
2025-11-145.46x
2025-11-135.44x
2025-11-125.42x
2025-11-115.41x
2025-11-105.26x
2025-11-075.22x
2025-11-065.23x
2025-11-055.20x
2025-11-045.22x
2025-11-035.21x
2025-10-315.28x
2025-10-305.28x
2025-10-295.22x
2025-10-285.23x
2025-10-275.31x
2025-10-245.32x
2025-10-235.37x
2025-10-225.38x
2025-10-215.48x
2025-10-205.53x
2025-10-175.51x
2025-10-165.48x
2025-10-155.46x
2025-10-145.45x
2025-10-135.45x
2025-10-105.45x
2025-10-095.46x
2025-10-085.42x
2025-10-075.40x
2025-10-065.38x
2025-10-035.39x
2025-10-025.32x
2025-10-015.32x
2025-09-305.30x
2025-09-295.20x
2025-09-265.15x
2025-09-255.10x
2025-09-245.07x
2025-09-235.07x
2025-09-225.01x
2025-09-195.06x
2025-09-185.00x
2025-09-175.09x
2025-09-165.07x
2025-09-155.09x
2025-09-125.11x
2025-09-115.12x
2025-09-105.05x
2025-09-095.08x
2025-09-085.11x
2025-09-055.12x
2025-09-045.13x
2025-09-035.11x
2025-09-025.11x
2025-08-295.08x
2025-08-285.04x
2025-08-275.07x
2025-08-265.07x
2025-08-255.12x
2025-08-225.14x
2025-08-215.13x
2025-08-205.13x
2025-08-195.10x
2025-08-185.06x
2025-08-155.07x
2025-08-145.02x
2025-08-135.01x
2025-08-124.97x
2025-08-114.99x
2025-08-084.98x
2025-08-074.93x
2025-08-064.91x
2025-08-054.91x
2025-08-044.92x
2025-08-014.82x
2025-07-314.75x
2025-07-304.82x
2025-07-294.84x
2025-07-284.79x
2025-07-254.85x
2025-07-244.88x
2025-07-234.74x
2025-07-224.71x
2025-07-214.61x
2025-07-184.60x
2025-07-174.58x
2025-07-164.63x
2025-07-154.36x
2025-07-144.41x
2025-07-114.41x
2025-07-104.43x
2025-07-094.39x
2025-07-084.38x
2025-07-074.37x
2025-07-034.39x
2025-07-024.38x
2025-07-014.38x
2025-06-304.30x
2025-06-274.29x
2025-06-264.28x
2025-06-254.29x
2025-06-244.28x
2025-06-234.26x
2025-06-204.22x
2025-06-184.24x
2025-06-174.29x
2025-06-164.37x
2025-06-134.42x
2025-06-124.40x
2025-06-114.37x
2025-06-104.40x
2025-06-094.37x
2025-06-064.36x
2025-06-054.32x
2025-06-044.31x
2025-06-034.34x
2025-06-024.37x
2025-05-304.37x
2025-05-294.32x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

Related Metrics

EV/EBITDAP/S RatioRevenueAll Metrics

About Johnson & Johnson

Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.

New Brunswick, NJ
138,100 employees
www.jnj.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato
View full financials